Wacker doubles production area at biologics plant
Wacker Chemie officially opens its new biologics plant in Jena, Germany.
The firm says the expansion will enable it to meet growing demand for biologically manufactured pharmaceuticals used to treat cancer, multiple sclerosis and hepatitis, among other indications.
The expansion, together with a building for process development and quality control completed last year, brings the total investment at the plant to Euro 18m.
Wacker has almost doubled the production area at the GMP-certified site. A new facility for product purification also allows up to three times higher product yields per batch.
"Demand for advanced biotech products is growing worldwide. Innovative, biotechnological processes such as Wacker's ESETEC secretion system allow us to meet demand and continue to shape the developments in biotechnology here in Germany," said Auguste Williams, a member of Wacker's Executive Board.
"We now have an ideal system for developing the sophisticated processes and analytical techniques of modern, microbe-based biologics," added Thomas Maier, managing director of Wacker Biotech.
"This allows Wacker to optimise the entire process chain, from lab operations to industrial GMP production. Customers thus benefit from a full process and analysis package provided from a single source. And with the expansion of our production capacities, we can now make our innovative ESETEC secretion technology available to more customers."
Traditional production methods aside, the focus of the new unit is on Wacker's ESETEC and DENSETEC proprietary technologies, which enable simpler, more cost-efficient and high-yield production of biologics for the pharmaceuticals industry.
You may also like
Manufacturing
Lonza appoints Hans Trees as Global Head of Communications
Read moreHans Trees will join Lonza as Global Head of Communications, Senior Vice President and Member of the Extended Executive Committee, effective 1 September 2026. Hans combines deep industry experience with a strong track record in stakeholder engagement, most recently serving as Global Head of External Engagement at Roche
Trending Articles
-
You need to be a subscriber to read this article.
Click here to find out more.
You may also like
Manufacturing
Lonza appoints Hans Trees as Global Head of Communications
Hans Trees will join Lonza as Global Head of Communications, Senior Vice President and Member of the Extended Executive Committee, effective 1 September 2026. Hans combines deep industry experience with a strong track record in stakeholder engagement, most recently serving as Global Head of External Engagement at Roche
Manufacturing
AlzeCure licenses Alzheimer’s candidate ACD680 to Lilly in deal worth up to $1bn
AlzeCure Pharma has entered a global licensing and collaboration agreement with Eli Lilly for its Alzheimer's disease candidate ACD680, securing a $10m upfront payment and potential milestone payments exceeding $1bn
Finance
GSK acquires Nuvalent for $10.6bn to accelerate NSCLC pipeline with FDA-reviewed ROS1 and ALK inhibitors
GSK has agreed to acquire clinical-stage oncology company Nuvalent for $10.6bn, securing two late-stage next-generation kinase inhibitors — zidesamtinib and neladalkib — currently under FDA review for potential 2026 approval in non-small cell lung cancer
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Research & Development
The path to commercial allogeneic iPSC therapies
The cell therapy sector is currently shifting from patient-specific autologous treatments toward off-the-shelf allogeneic cell therapies. Although this transition is helping to democratise access to treatments, it introduces several challenges in terms of controlling complex biology at a commercial scale